NetraMark Holdings ( (TSE:AIAI) ) just unveiled an announcement.
NetraMark Holdings Inc. has announced a strategic global agreement with Worldwide Clinical Trials to enhance clinical trial design using AI-powered precision analytics. This partnership will integrate NetraMark’s NetraAI platform into Worldwide’s clinical trial offerings, initially targeting Phase 2 and select Phase 3 neuroscience and oncology trials, with plans for broader application. The collaboration aims to improve trial efficiency, patient targeting, and regulatory success, ultimately accelerating the development of personalized therapies.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leading artificial intelligence company specializing in precision analytics for the pharmaceutical industry. The company focuses on transforming clinical trials through its proprietary NetraAI platform, which is designed to optimize trial processes by uncovering hidden patient subpopulations within complex datasets.
YTD Price Performance: 21.43%
Average Trading Volume: 9,392
Technical Sentiment Signal: Strong Sell
For detailed information about AIAI stock, go to TipRanks’ Stock Analysis page.